Income Statement (IMMUNOGEN)

IMMUNOGEN NEWS

AbbVie Inc. (ABBV): A Bull Case Theory By Ricardo - 2 weeks ago

We came across a bullish thesis on AbbVie Inc. (ABBV) on Substack by Magnus Ofstad. In this article, we will summarize the bulls thesis on ABBV. AbbVie Inc. (ABBV)'s share was trading at $198.47 as o… [+2277 chars]...

Read more
Antibody Drug Conjugates Market and Forecast to 2030: Trends, Developments and Shares by Type of ADC, Application, Region and Company By Research - 3 weeks ago

Dublin, April 25, 2025 (GLOBE NEWSWIRE) -- The "Antibody Drug Conjugates Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F" report has been added to ResearchAndMarke… [+7225 chars]...

Read more
CytomX Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock By Site Author - 1 week ago

SOUTH SAN FRANCISCO, Calif., May 12, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a leader in the field of masked, conditionally activated biologic therapeutics, today announced … [+5658 chars]...

Read more
Pharmaceuticals and Biotechnology Co-promotion and Co-marketing Agreement Trends Analysis and Directory of Deals 2016-2025 By Research - 1 week ago

Dublin, May 09, 2025 (GLOBE NEWSWIRE) -- The "Co-promotion and Co-marketing in Pharmaceuticals and Biotechnology 2016-2025" has been added to ResearchAndMarkets.com's offering. This report contains … [+5806 chars]...

Read more
Anti-Cancer MAbS Market Research Report 2025: Rising Cancer Incidence Spurs Demand for Targeted Anti-Cancer MAbS Treatments - Historic Trends and Forecasts, 2019-2024, 2024-2029F, 2034F By Research - 1 week ago

Dublin, May 08, 2025 (GLOBE NEWSWIRE) -- The "Anti-Cancer MAbS Market Report 2025" has been added to ResearchAndMarkets.com's offering. The anti-cancer monoclonal antibodies (mAbs) market is experie… [+6226 chars]...

Read more
A phase I, open-label, multicentre, first-in-human study to evaluate safety, pharmacokinetics and efficacy of AMG 404, a PD-1 inhibitor, in patients with advanced solid tumours By Site Author - 2 weeks ago

Competing interests TP: honorarium: Amgen, Servier, MSD; advisory board: Amgen, Servier, MSD and BMS. IL: Roche, MSD, Amgen, BMS, Pfizer, Ryvu, Takeda Siropa, Rhizen, Menarini, Incyte and MacroGenics… [+5619 chars]...

Read more
Top Stock
CurrencyPrice Chg
BA
203.28 -4.39
-2.12%
CVX
135.56 -1.71
-1.25%
CAT
342.34 -7.15
-2.05%
INTC
20.73 -0.55
-2.56%
MSFT
453.55 -4.62
-1.01%
DIS
110.32 -2.04
-1.81%
DOW
28.72 -1.08
-3.61%
CSCO
63.23 -0.19
-0.3%
GS
594.33 -12.19
-2.01%